What is a sensible monitoring routine for dulaglutide over two weeks?

Details up front: dulaglutide · two weeks.

I am trying to build something sustainable rather than something thorough that I will abandon.

I have already decided the broad direction; this is about the specifics.

How would you structure this, and what thresholds would you set in advance?

Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.

Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.

Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.

External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.

One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.

edited 29 Sept 2024 by esben_lykke — added the citation requested in comments

Before reacting to any single value, check whether it is outside the interval by an amount larger than the assay's own variation.

Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.

It helps to be literal here: a twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.

Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.

Keep the full report, not the number. You will need the units and the interval later.

The relevant statistical point is that a ninety-five per cent reference interval means one analyte in twenty will read out of range in a healthy person by construction.

Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.

Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.

Baseline first, then a repeat under identical conditions. Everything else is secondary.

The honest position is that most people order too many analytes and too few time points, when the reverse would be more informative.

A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.

Research-use compounds are not approved for human use, and no panel makes that safer.

Same laboratory, same time, same fasting state, or the comparison is not a comparison.